O	0	10	Randomized
O	11	21	controlled
O	22	27	trial
O	28	30	of
B-intervention	31	37	weight
I-intervention	38	42	loss
O	43	49	versus
B-control	50	55	usual
I-control	56	60	care
O	61	63	on
O	64	72	telomere
O	73	79	length
O	80	82	in
O	83	88	women
O	89	93	with
O	94	100	breast
O	101	107	cancer
O	107	108	:
O	109	112	the
O	113	122	lifestyle
O	122	123	,
O	124	132	exercise
O	132	133	,
O	134	137	and
O	138	147	nutrition
O	148	149	(
O	149	153	LEAN
O	153	154	)
O	155	160	study
O	160	161	.

O	162	166	Some
O	167	174	studies
O	175	182	suggest
O	183	187	that
O	188	196	telomere
O	197	207	shortening
O	208	211	may
O	212	214	be
O	215	225	associated
O	226	230	with
O	231	240	increased
O	241	247	breast
O	248	254	cancer
O	255	259	risk
O	260	263	and
O	264	273	mortality
O	273	274	.

O	275	282	Obesity
O	283	285	is
O	286	290	also
O	291	301	associated
O	302	306	with
O	307	316	increased
O	317	323	breast
O	324	330	cancer
O	331	335	risk
O	336	339	and
O	340	349	mortality
O	349	350	.

O	351	354	Few
O	355	362	studies
O	363	367	have
O	368	376	examined
O	377	384	changes
O	385	387	in
O	388	396	telomere
O	397	403	length
O	404	406	in
O	407	417	overweight
O	418	420	or
O	421	426	obese
O	427	433	breast
O	434	440	cancer
O	441	450	survivors
O	450	451	.

O	452	455	The
O	456	463	purpose
O	464	466	of
O	467	470	our
O	471	476	study
O	477	480	was
O	481	483	to
O	484	491	examine
O	492	495	the
O	496	502	effect
O	503	505	of
O	506	507	a
O	508	509	6
O	509	510	-
O	510	515	month
O	516	520	diet
O	520	521	-
O	522	525	and
O	526	534	exercise
O	534	535	-
O	535	542	induced
O	543	549	weight
O	550	554	loss
O	555	567	intervention
O	568	574	versus
O	575	580	usual
O	581	585	care
O	586	588	on
O	589	597	telomere
O	598	604	length
O	605	607	in
B-eligibility	608	614	breast
I-eligibility	615	621	cancer
I-eligibility	622	631	survivors
O	631	632	.

B-total-participants	633	636	151
O	637	643	breast
O	644	650	cancer
O	651	660	survivors
O	661	665	with
O	666	670	body
O	671	675	mass
O	676	681	index
O	682	683	(
O	683	686	BMI
O	686	687	)
O	688	689	≥
O	690	692	25
O	693	695	kg
O	695	696	/
O	696	698	m2
O	699	703	were
O	704	712	randomly
O	713	721	assigned
O	722	724	to
O	725	726	a
O	727	728	6
O	728	729	-
O	729	734	month
O	735	741	weight
O	742	746	loss
O	747	759	intervention
O	760	761	(
O	761	762	n
O	763	764	=
B-intervention-participants	765	767	93
O	767	768	)
O	769	771	or
O	772	774	to
O	775	780	usual
O	781	785	care
O	786	787	(
O	787	788	n
O	789	790	=
B-control-participants	791	793	58
O	793	794	)
O	794	795	.

O	796	803	Fasting
O	804	809	blood
O	810	817	samples
O	817	818	,
O	819	825	height
O	825	826	,
O	827	833	weight
O	833	834	,
O	835	843	physical
O	844	852	activity
O	852	853	,
O	854	857	and
O	858	862	diet
O	863	867	were
O	868	876	measured
O	877	879	at
O	880	888	baseline
O	889	892	and
O	893	894	6
O	894	895	-
O	895	901	months
O	901	902	.

O	903	911	Relative
O	912	920	telomere
O	921	927	length
O	928	929	(
O	929	932	RTL
O	932	933	)
O	934	937	was
O	938	946	measured
O	947	949	by
O	950	962	quantitative
O	962	963	-
O	963	973	polymerase
O	974	979	chain
O	980	988	reaction
O	989	990	(
O	990	994	qPCR
O	994	995	)
O	996	1000	done
O	1001	1003	on
O	1004	1009	buffy
O	1010	1014	coat
O	1014	1015	-
O	1015	1024	extracted
O	1025	1032	genomic
O	1033	1036	DNA
O	1036	1037	.

O	1038	1042	Mean
O	1043	1051	baseline
O	1052	1054	to
O	1055	1056	6
O	1056	1057	-
O	1057	1062	month
O	1063	1070	changes
O	1071	1075	were
O	1076	1084	compared
O	1085	1092	between
O	1093	1099	groups
O	1100	1101	(
O	1101	1110	intention
O	1110	1111	-
O	1111	1113	to
O	1113	1114	-
O	1114	1119	treat
O	1119	1120	)
O	1121	1126	using
O	1127	1138	generalized
O	1139	1149	estimating
O	1150	1159	equations
O	1159	1160	.

O	1161	1169	Complete
O	1170	1178	telomere
O	1179	1183	data
O	1184	1188	were
O	1189	1198	available
O	1199	1201	in
B-total-participants	1202	1205	125
O	1206	1218	participants
O	1218	1219	.

O	1220	1225	Women
O	1226	1230	were
B-age	1231	1233	58
I-age	1234	1235	±
I-age	1236	1237	8
I-age	1238	1243	years
O	1243	1244	,
O	1245	1249	with
O	1250	1253	BMI
O	1254	1256	33
O	1256	1257	.
O	1257	1258	0
O	1259	1260	±
O	1261	1262	6
O	1262	1263	.
O	1263	1264	2
O	1265	1267	kg
O	1267	1268	/
O	1268	1270	m2
O	1271	1274	and
O	1275	1279	were
O	1280	1281	2
O	1281	1282	.
O	1282	1283	9
O	1284	1285	±
O	1286	1287	2
O	1287	1288	.
O	1288	1289	5
O	1290	1295	years
O	1296	1300	from
O	1301	1310	diagnosis
O	1310	1311	;
O	1312	1314	90
O	1314	1315	%
O	1316	1320	were
B-ethinicity	1321	1324	non
I-ethinicity	1324	1325	-
I-ethinicity	1325	1333	Hispanic
I-ethinicity	1334	1339	white
O	1339	1340	,
O	1341	1344	and
O	1345	1347	76
O	1347	1348	%
O	1349	1352	had
O	1353	1358	stage
O	1359	1360	0
O	1360	1361	/
O	1361	1362	I
O	1363	1369	breast
O	1370	1376	cancer
O	1376	1377	.

O	1378	1383	After
O	1384	1385	6
O	1386	1392	months
O	1392	1393	,
O	1394	1399	women
O	1400	1410	randomized
O	1411	1413	to
O	1414	1420	weight
O	1421	1425	loss
O	1426	1429	had
B-iv-bin-percent	1430	1431	3
I-iv-bin-percent	1431	1432	%
B-outcome	1433	1441	telomere
I-outcome	1442	1453	lengthening
O	1454	1462	compared
O	1463	1465	to
B-cv-bin-percent	1466	1467	5
I-cv-bin-percent	1467	1468	%
O	1469	1479	shortening
O	1480	1482	in
O	1483	1486	the
O	1487	1492	usual
O	1493	1497	care
O	1498	1503	group
O	1504	1505	(
O	1505	1506	p
O	1507	1508	=
O	1509	1510	0
O	1510	1511	.
O	1511	1513	12
O	1513	1514	)
O	1514	1515	.

O	1516	1521	Among
O	1522	1527	women
O	1528	1532	with
O	1533	1538	stage
O	1539	1540	0
O	1540	1541	/
O	1541	1542	I
O	1542	1543	,
O	1544	1547	the
O	1548	1560	intervention
O	1561	1566	group
O	1567	1578	experienced
B-iv-bin-percent	1579	1580	7
I-iv-bin-percent	1580	1581	%
B-outcome	1582	1590	telomere
I-outcome	1591	1602	lengthening
O	1603	1611	compared
O	1612	1614	to
B-cv-bin-percent	1615	1616	8
I-cv-bin-percent	1616	1617	%
O	1618	1628	shortening
O	1629	1631	in
O	1632	1635	the
O	1636	1641	usual
O	1642	1646	care
O	1647	1652	group
O	1653	1654	(
O	1654	1655	p
O	1656	1657	=
O	1658	1659	0
O	1659	1660	.
O	1660	1662	01
O	1662	1663	)
O	1663	1664	.

O	1665	1667	No
O	1668	1680	intervention
O	1681	1687	effect
O	1688	1691	was
O	1692	1700	observed
O	1701	1703	in
O	1704	1709	women
O	1710	1714	with
O	1715	1720	stage
O	1721	1723	II
O	1723	1724	/
O	1724	1727	III
O	1728	1734	breast
O	1735	1741	cancer
O	1741	1742	.

O	1743	1746	Our
O	1747	1755	findings
O	1756	1763	suggest
O	1764	1765	a
O	1766	1772	weight
O	1773	1777	loss
O	1778	1790	intervention
O	1791	1793	in
O	1794	1799	stage
O	1800	1801	0
O	1802	1805	and
O	1806	1807	1
O	1808	1814	breast
O	1815	1821	cancer
O	1822	1831	survivors
O	1832	1835	may
O	1836	1840	lead
O	1841	1843	to
O	1844	1852	telomere
O	1853	1864	lengthening
O	1864	1865	,
O	1866	1874	compared
O	1875	1877	to
O	1878	1879	a
O	1880	1890	shortening
O	1891	1893	in
O	1894	1899	their
O	1900	1905	usual
O	1906	1910	care
O	1911	1923	counterparts
O	1923	1924	.
